Trial Profile
LAM Pilot Study With Imatinib Mesylate
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Everolimus; Sirolimus
- Indications Lymphangioleiomyomatosis
- Focus Therapeutic Use
- Acronyms LAMP-1
- 20 May 2020 Primary endpoint has not been met. (Serum VEGF-D)
- 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society
- 09 Sep 2019 Status changed from active, no longer recruiting to completed.